Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction

Wei Gang Tong, Hagop Kantarjian, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Gautam Borthakur, Jianqin Shan, Sherry Pierce, Mary Beth Rios, Jorge Cortes

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Fingerprint

Dive into the research topics of 'Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction'. Together they form a unique fingerprint.

Medicine & Life Sciences